Condition: Colorectal Cancer · Sponsor: AbbVie
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants will then be randomized into 2 groups called treatment arms. One group will receive telisotuzumab adizutecan with bevacizumab in different doses. Another group will receive standard of care (SOC), trifluridine and tipiracil (LONSURF), with Bevacizumab. Up to approximately 700 adult participants with refractory mCRC, will be enrolled in the study in approximately 125 sites globally. In this Phase 3, one of two groups will receive doses of Intravenous (IV) telisotuzumab adizutecan + bevacizumab and other group will receive oral SOC of trifluridine/tipiracil (LONSURF)+ Intravenous (IV) bevacizumab. The study will run for a duration of approximately of 36 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaire…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Astera Cancer Care /ID# 279532 | East Brunswick, New Jersey, United States | Recruiting |
| Northwell Health Center for Advanced Medicine. /ID# 279590 | Lake Success, New York, United States | Recruiting |
| Compass Oncology - Rose Quarter /ID# 280127 | Portland, Oregon, United States | Recruiting |
| University Of Washington-Fred Hutchinson Cancer Center - Seattle /ID# 281451 | Seattle, Washington, United States | Recruiting |
| Imelda Ziekenhuis /ID# 279333 | Bonheiden, Antwerpen, Belgium | Recruiting |
| Algemeen Ziekenhuis klina /ID# 279331 | Brasschaat, Antwerpen, Belgium | Not Yet Recruiting |
| Universitair Ziekenhuis Antwerpen /ID# 279334 | Edegem, Antwerpen, Belgium | Recruiting |
| Institut Jules Bordet /ID# 279406 | Anderlecht, Brussels Capital, Belgium | Recruiting |
| Grand Hopital de Charleroi - Les Viviers /ID# 279336 | Charleroi, Hainaut, Belgium | Recruiting |
| AZ Maria Middelares /ID# 280141 | Ghent, Oost-Vlaanderen, Belgium | Recruiting |
| AZ-Delta. /ID# 279329 | Roeselare, West-Vlaanderen, Belgium | Recruiting |
| National Cancer Center Hospital East /ID# 279917 | Kashiwa-shi, Chiba, Japan | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07525206